However, the increase in plasma BCAA that results from either the decreased expression of BCAA metabolic enzymes [13] or the increased expression of BCKDK may offer a less invasive biomarker, potentially of particular use in cancers where increased BCAA levels have been associated with increased cancer risk or reduced survival [11, 13, 14]. The gene discussed is ARID4B; the disease is cancer.